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Formation of DNAAdducts and Induction of
Mutations in Rats Treated with Tumorigenic
Doses of 1,6-Dinitropyrene
Frederick A. Beland, Nancy F. Fullerton, Beverly A. Smith, and
Robert H. Heflich
National Center for Toxicological Research, Jefferson, Arkansas
1,6-Dinitropyrene, a component of diesel exhaust, is a lung carcinogen in male F344 rats following a single intrapulmonary administration. In this
study, rats were treated with tumorigenic doses of 1,6-dinitropyrene to establish dose-response relationships for the formation of DNA adducts in
target (lung) and nontarget (liver) tissues and for the induction of 6-thioguanine-resistant mutations in spleen T-lymphocytes. One week after treat-
ment with 0.3, 1, 3, 10, 30, 100, or 150 pg of 1,6-dinitropyrene, dose-responsive DNA binding was measured in lung and liver with binding in the
lung being 10-fold higher than in the liver. In the lung, a 2-fold increase in dose resulted in a 1.8-fold increase in DNA binding at treatments up to
30 pg of 1,6-dinitropyrene, while in the liver, a 2-fold increase in 1,6-dinitropyrene produced a 2-fold increase in DNA binding at doses up to the 10 pg
treatment. Higher doses of 1,6-dinitropyrene resulted in proportionally smaller increases in adduct formation in the two tissues. When measured
21 weeks after treatment, mutations in T-lymphocytes increased with doses up to 100 pg of 1,6-dinitropyrene, but the response was nonlinear
throughout the dose range. These findings indicate that concentrations of 1,6-dinitropyrene that produce a dose-dependent induction of lung tumors
also result in a dose-dependent formation of DNA adducts and induction of lymphocyte mutations but that the dose-response curves for DNA bind-
ing and mutations are different. - Environ Health Perspect 102(Suppl 6):185-189 (1994)
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Introduction
Epidemiologic data have suggested an asso-
ciation between exposure to diesel exhaust
and the induction oflung and bladder can-
cer in humans (1-3). For example, in a
large retrospective cohort study involving
more than 50,000 railroad workers,
Garshick et al. (4) found a slight but statis-
tically significant increase in lung tumors
that appeared to be related to diesel expo-
sure. Likewise, Boffetta et al. (5) reported
significant increases in lung cancer for
miners and heavy equipment operators
who reported exposure to diesel emissions,
and Hayes et al. (6) found an elevated
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incidence ofbladder cancer in truck drivers
and railroad workers with more than 20
years ofexposure to diesel exhaust.
Diesel emissions are a complex mixture
composed of particulate, gas, and vapor
phases (1,2). Because lung tumors are not
induced in experimental animals exposed
to only the gas and vapor phases, emphasis
has been placed on the toxic properties of
the particulates. The particulate phase of
diesel exhaust contains a number of poly-
cyclic aromatic hydrocarbons (PAHs),
including anthracene, pyrene, benz[a]anthra-
cene, and benzo[a]pyrene. Certain ofthese
PAHs, as exemplified by benzo[a]pyrene,
are clearly carcinogenic in experimental
animals and may contribute to the
increased incidence of lung and bladder
cancer observed in individuals exposed to
diesel emissions. Nitro PAHs are another
group of chemicals detected in diesel par-
ticulates. These compounds, which are
formed during the combustion process as a
result of the reaction of nitrogen oxides
with PAHs, are found typically at much
lower concentrations than PAHs. Pyrene, for
example, occurs at approximately 5000 pg/g
ofparticulate extract, while its mononitra-
tion and dinitration products, 1-nitropy-
rene and 1,6-dinitropyrene, are detected at
about 75 and 0.40 pg/g of particulate
extract, respectively. Although nitro PAHs
are found at much lower levels than PAHs,
certain members of this class are powerful
mutagens and carcinogens. 1,6-Dinitro-
pyrene, for instance, is one of the most
mutagenic compounds tested in the Ames
Salmonella reversion assay and it induces
tumors at a number of sites in a variety of
experimental animals (7-12). Because
nitro PAHs are interrelated through metab-
olism to aromatic amines (13), a class of
carcinogens known to cause bladder cancer
in humans (3,14), they may contribute to
the increased incidence of both lung and
bladder tumors in individuals exposed to
diesel exhaust.
Recently there has been considerable
effort to develop biomarkers for detecting
carcinogen exposure with the hope that
this will allow a more rapid identification
and estimation ofthe risk to humans (15).
Two markers that have received much
attention are DNA (16,17) and protein
(18) adducts, and a number ofreports have
appeared documenting correlations
between carcinogen exposure and adduct
concentrations (16-21). While valuable,
DNA adduct and protein adduct measure-
ments suffer from the limitation that, as a
result ofDNA repair as well as protein and
cell turnover, only recent exposures can be
assessed. An approach that has the poten-
tial to indicate more than recent carcinogen
exposures is to measure the biologic effects
resulting from DNA adduct formation, in
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particular the induction of lymphocyte
mutations (22). An advantage ofthis tech-
nique is that ifmutations are induced in a
stem cell population, they may be detected
for periods long after the initial carcinogen
insult. Furthermore, molecular analysis of
the mutants may reveal patterns indicative
of the specific carcinogen inducing the
mutation.
We recently reported (23,24) the for-
mation of DNA adducts and T-lympho-
cyte mutations after the administration of
either 30 or 100 pg of 1,6-dinitropyrene
directly to the lungs ofF344 rats according
to a protocol known to induce lung tumors
(10,11). In lung and spleen lymphocytes,
one major adduct, N-(deoxyguanosin-8-yl)-
1-amino-6-nitropyrene, was detected. The
levels ofthis adduct reached a maximum 3
to 7 days following treatment, were dose-
dependent in spleen lymphocytes but not
in lung, and decreased to 25 to 50% of
peak values by 28 days after dosing.
Mutations were assayed at the hypoxan-
thine-guanine phosphoribosyltransferase
(hprt) locus in spleen T-lymphocytes for up
to 51 weeks following a similar treatment
with 1,6-dinitropyrene. Compared to solvent-
treated controls, 1,6-dinitropyrene induced
a significant increase in mutant frequency
with the 100 pg dose typically giving 2-fold
more mutants than the 30-pg treatment.
With both doses, the mutant frequency
increased until 21 weeks after dosing,
remained constant until week 40, and then
began to decrease, but even almost 1 year fol-
lowing treatment there was still a signifi-
cantly greater mutant frequency in the
1,6-dinitropyrene-treated rats as compared
to the controls. As a continuation of these
experiments, we now have examined the
dose dependence ofadduct formation and
mutation induction. Specifically, we have
treated rats with seven doses of 1,6-dini-
tropyrene between 0.3 to 150 pg and
assessed DNA adduct levels 1 week after
treatment, while the extent of mutation
induction was determined 21 weeks follow-
ing dosing.
Materials and Methods
DNAAdductAnalyses
Male F344 rats (12 weeks old; three to five
animals per dose group, from the breeding
colony at the National Center for Toxico-
logical Research, Jefferson, AR) were anes-
thetized with a mixture of ketamine and
xylazine (25), and subjected to a left lateral
thoracotomy. [4,5,9,10-3H]1,6-Dinitro-
pyrene (0, 0.3, 1, 3, 10, 30, 100, or 150
pg; 1257 mCi/mmole) in 50 pl ofbeeswax
and tricaprylin (1:1) was then administered
using the lung implantation method of
Stanton et al. (26) as described by
Iwagawa and co-workers (11). Seven days
after treatment, the animals were exposed
to carbon dioxide, decapitated, and the
lungs, livers, and spleens were quickly
excised. Lung and liver nuclei were pre-
pared using the method of Basler et al.
(27), and spleen lymphocytes were isolated
by the technique ofAidoo et al. (28).
DNA was extracted from the nuclei and
cells by slight modification ofthe method
reported in Beland et al. (29). The DNA
was quantified by UV spectrometry, and
the extent ofadduct formation was deter-
mined by liquid scintillation counting.
When indicated, 32P-postlabeling assays
were conducted as described in Smith et al.
(23,30).
Analysis ofMutation Induction atthe
prtLocus ofSpleenLymphocytes
Additional rats (two per group) were
treated identically with the same doses
described above. Twenty-one weeks follow-
ing dosing, the rats were euthanized by
exposure to carbon dioxide, their spleens
were removed aseptically, and lymphocytes
were isolated. Each rat was processed inde-
pendently. The number ofT-lymphocytes
with mutations at the hprt locus, as evi-
denced by growth ofthe lymphocytes in the
presence of the purine analog 6-thio-
guanine, was determined by the limiting
dilution clonal assaydescribed in Aidoo et al.
(28), modified byusingconditioned medium
as a source ofT-cell growth factor (31).
Results
Analysis ofthe Bindingof
1,6-Dinitropyrene to Lung, Liver, and
SpleenLymphocyte DNA
The extent ofadduct formation, as a func-
tion of dose, in lung DNA of male F344
rats 7 days following the implantation of
1,6-dinitropyrene is shown in Figure 1A.
From 0 through 30 pg of 1,6-dinitropy-
rene, the amount ofbinding to lung DNA
increased with dose such that a 2-fold
increase in the amount of 1,6-dinitropy-
rene resulted in a 1.8-fold increase in bind-
ing (r=0.96). At doses above 30 pg of
1,6-dinitropyrene, the amount of binding
still increased with dose, but the rate of
increase was much less than that observed at
the lower doses. In previous work (23), lung
DNA from animals treated in an identical
manner with 30 or 100 pg of 1,6-dinitro-
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Figure 1. DNA binding in male F344 rat lung (A) and
liver (B) 1 week after treatment with [3H11,6-dinitro-
pyrene.
pyrene was analyzed by32P-postlabeling and
the only adduct detected was N-(deoxy-
guanosin-8-yl)- 1-amino-6-nitropyrene.
The total extent ofadduct formation in
the liver (Figure 1B) from 1,6-dinitropyrene
was approximately 10% ofthat observed in
the lung (Figure 1A). As with the lung
DNA, the extent of binding as a function
ofdose was described by a biphasic curve.
From 0 through 10 pg of 1,6-dinitropyrene,
there was a linear increase (r=0.97) with a
2-fold increase in dose, resulting in a 2-fold
increase in binding. Above 10 pg of 1,6-
dinitropyrene, the increase in adduct con-
centration was still linear, but the rate was
much lower than that occurring at lower
doses. 32P-Postlabeling analyses of liver
DNA indicated the presence of one major
adduct with the same elution characteris-
tics as N-(deoxyguanosin-8-yl)-1-amino-6-
nitropyrene.
The extent of DNA binding also was
assessed in the spleen lymphocytes. When
treated with 150 pg of 1,6-dinitropyrene,
the binding levels were 0.13 ± 0.04 fmole
adduct/pg DNA. Comparable values for 30
and 100 pg of 1,6-dinitropyrene were 0.07
± 0.02 and 0.14 ± 0.09 fmole adduct/pg
DNA. The yield of DNA from the spleen
lymphocytes was insufficient (-500 pg) to
measure the extent of binding based upon
the amount of 3H incorporated at doses
lower than 30 pg of 1,6-dinitropyrene.
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Figure 2. 6-Thioguanine-resistant mutant frequency in
lymphocytes cultured from the spleens of male F344
rats 21 weeks after treatment with [3H11,6-dinitropy-
rene.
Analysis ofMutationInduction atthe
hprt Locus ofSpleenLymphocytes
The mutant frequency, as a function of
dose, 21 weeks after implanting 1,6-dini-
tropyrene, is shown in Figure 2. At each
dose examined, the number of6-thiogua-
nine resistant T-lymphocytes was greater
than that observed in the solvent-treated
controls and, with the exception ofthe 0.3-
pg dose, these increases were statistically
significant (p < 0.01). As with the DNA
binding, the mutant frequency tended to
increase with dose; however, the response
was not linear and actually decreased at the
highestdose of150 pgof1,6-dinitropyrene.
Discussion
In previous experiments (23,24), we
applied 30 or 100 pg of 1,6-dinitropyrene
directly into the lungs of F344 rats to
determine the kinetics ofadduct formation
in target and nontarget tissues and the
extent of mutation induction in spleen T-
lymphocytes. The results ofthis work indi-
cated that maximum DNA adduct levels
occurred 3 to 7 days after treatment, while
the greatest number of mutant spleen T-
lymphocytes was detected 21 weeks follow-
ing treatment. Using these time points, we
conducted a dose-response study that
included the doses used by Iwagawa et al.
(3-150 pg of 1,6-dinitropyrene) (11) to
induce lung tumors in F344 rats. In addi-
tion, two lower doses were administered
(0.3, 1 pg) to obtain information on the
shape ofthe dose-response curve at doses
where it would be prohibitively expensive
to conduct a tumorigenesis assay.
In the target tissue, the lung, the extent
of DNA binding increased linearly with
doses up to 30 pg of 1,6-dinitropyrene.
Beyond this dose, the adduct levels still
increased, but the rate of increase was
much lower than that observed at lower
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Figure 3. Lung tumor incidence as a function of lung
DNA adduct formation in male F344 rats treated with
various doses of 1,6-dinitropyrene. Lung tumor data
from lwagawa et al. (11).
doses. A similar biphasic dose-response
curve also was observed in a nontarget tissue,
the liver. In this organ, the total binding
was approximately 10% of that found in
the lung, but again there was a steep
increase in binding from 0.3 to 10 pg of
1,6-dinitropyrene followed by a slower
increase in binding at the higher doses of
1,6-dinitropyrene. In spleen lymphocytes
we were unable to measure adduct forma-
tion below 30 pg of 1,6-dinitropyrene
because of the low levels of binding cou-
pled with the relatively low (as compared
to the liver) yield ofDNA. As in our previ-
ous study (23), there was a 2-fold increase
in binding between 30 and 100 pg of 1,6-
dinitropyrene. Because the binding did not
increaseany further at the 150 pg dose, this
suggests that a biphasic dose-response for
adduct formation also may be occurring in
these cells. We are presently attempting to
describe the entire dose-response profile in
spleen lymphocyte DNA by using 32 p-
postlabeling assays.
Biphasic dose-response curves for
adduct formation, with linear increases at
low doses but proportionally smaller
increases at higher doses, have been
observed with other carcinogens, including
4-aminobiphenyl in female mouse liver
(32), NfN-diethylnitrosamine in male rat
liver (33), and 4-(methyl-nitrosoamino)-1-
(3-pyridyl)-1-butanone in male rat lung
(34). With these carcinogens, the decreased
rates ofadduct formation at higher doses
have been attributed to metabolic satura-
tion, the induction oftoxicity and cell pro-
liferation, or both. Both of these
mechanisms could contribute to the bipha-
sic response in the lungs of rats treated
with 1,6-dinitropyrene, although because
of the relatively low doses administered,
cell proliferation as a result ofcytotoxicity
is perhaps unlikely. These mechanisms also
could contribute to the nonlinearity in
adduct formation observed in the liver and
in spleen lymphocytes. In addition, there
may be impaired clearance ofthe 1,6-dini-
tropyrene from the lungs at higher carcino-
gen doses.
Upon treatmentwith 1,6-dinitropyrene,
the induction ofT-lymphocyte mutants
tended to increase with dose, but as com-
pared to the DNA binding results, the
response was not linear at low doses ofcar-
cinogen. The curvilinear response through-
out the entire dose range may be a direct
reflection ofthe extent of DNA binding,
which we have not been able to determine
at low doses. It also could be a reflection of
toxicity at the higher doses of 1,6-dinitro-
pyrene; thus, binding to lymphocyte DNA
could be linear but an increasing propor-
tion ofcells could be lost because ofcyto-
toxicity as the dose was increased.
The doses selected for this study corre-
spond to those used by Iwagawa et al. (11)
to induce lung tumors in male F344 rats.
In their bioassay, 10 pg of 1,6-dinitropyrene
induced a 13% incidence oflung tumors,
and the incidence increased in a relatively
linear manner to 85% at the 100 pg dose.
At 150 pg of 1,6-dinitropyrene, the inci-
dence decreased slightly but this may
reflect the fact that there were very few ani-
mals in this group. (Although tumorigene-
sis was not the objective ofthe present study,
as part of our initial time-course experi-
ment, we noted the development of lung
tumors in one rat 32 weeks after adminis-
tering 100 pg of 1,6-dinitropyrene and in
two rats 51 weeks after dosing with 30 and
100 pg of 1,6-dinitropyrene). Because
DNA adduct levels were measured at the
same doses used in the bioassay, it is possible
to relate the extent ofDNA adduct forma-
tion to the tumorincidence; such an analysis
is shown in Figure 3. These results indicate
that a 50% incidence of lung tumors
would be associated with a concentration
ofapproximately 1.3 fmole ofN-(deoxy-
guanosin-8-yl)-1-amino-6-nitropyrene/pg
DNA. A similar analysis has been con-
ducted with a number ofother carcinogens
(35) and, for most compounds, the adduct
level associated with a 50% tumor inci-
dence was considerably higher (> 100
fmoles/pg DNA) than that found for 1,6-
dinitropyrene. An exception to this high
level ofbinding was aflatoxinBI and, inter-
estingly, both this carcinogen and 1,6-dini-
tropyrene induce tumors at very low
concentrations. In our study, we also
detected DNA adducts at dose levels (e.g.,
3 pg of 1,6-dinitropyrene) where Iwagawa
et al. (11) did not detect lung tumors.
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Assuming a linear relationship between the
DNA adduct levels and the induced tumor
incidence, our data predicts that 3 pg of
1,6-dinitropyrene should induce approxi-
mately 5% lung tumors. Iwagawa et al. (11)
would have had to treat considerably more
rats than the 30 animals they used to detect
such a difference.
F344 rats exposed to 2.2 to 7.1 mg/mi3
diesel emissions for 24 to 30 months
develop an increased incidence of lung
tumors (2). Assuming that all ofthe partic-
ulate-associated dinitropyrenes was bio-
available, it can be estimated that each rat
received 4 to 27 ng of 1,6-dinitropyrene
and 12 to 83 ng of 1,3-, 1,6-, and 1,8-dini-
tropyrene during this exposure period.
Although we detected significant levels of
DNA binding and lymphocyte mutations
at 1,6-dinitropyrene doses below those
Iwagawa et al. (11) found to be tumori-
genic, these treatment levels of 0.3 and 1
pg of 1,6-dinitropyrene are still approxi-
mately one order ofmagnitude greater than
the 1,6-dinitropyrene exposure expected
from diesel emissions. This suggests that
DNA adducts or lymphocyte mutations
produced by 1,6-dinitropyrene (or dini-
tropyrenes) alone may not be a sufficiently
sensitive biomarker for diesel exposure.
Treatment-related DNA adducts have been
reported in rats exposed to diesel exhausts
(36-38), and there are other highly geno-
toxic compounds, such as benzo[a]pyrene,
found at far greater concentrations than
dinitropyrenes in diesel particles (1). DNA
adducts or mutations produced by these or
other diesel-associated compounds may
serve as more useful biomarkers for diesel
exposure. It should also be noted that we
are assuming a linear dose-response to very
low concentrations ofdinitropyrenes. With
other compounds, in particular the bladder
carcinogen 4-aminobiphenyl, DNA adduct
levels in humans exposed to relatively low
levels of4-aminobiphenyl through cigarette
smoke are much higher than would have
been predicted from comparatively high
dose animal exposures (39).
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